Consumption of cashew nut induced anxiolytic-like behavior in dyslipidemic rats consuming a high fat diet.

This study aimed to evaluate the effect of cashew nut consumption on anxiety-like behavior in dyslipidemic rats. The groups formed were: Control (CONT), Dyslipidemic (DL) and Dyslipidemic cashew nuts (DLCN). Tests to assess anxiety parameters were performed after the treatment period. Brain fatty acid profiles were analyzed. The animals in the DLCN group showed more rearing than DL, without differing from the CONT and less grooming than either the DL and CONT in the Open Field. In the Elevated Plus Maze, DLCN spent more time on the open arms and in the central area compared to the other groups. As for brain fatty acids, there was a reduction in polyunsaturated fatty acids for the DLCN compared to the other groups. The cashew nut, rich in fatty acids, phenolic and flavonoid compounds, reduced the anxiogenic-like behavior caused by dyslipidemia in rats without altering brain fatty acids.

Cashew nuts (Anacardium occidentale L.) decrease visceral fat, yet augment glucose in dyslipidemic rats.

The objective of this study was to evaluate the biological effects of roasted Cashew nuts consumption on biochemical and murinometric parameters in dyslipidemic rats receiving lipid supplementation. Young male rats were randomly assigned to three experimental groups (n = 10). The Control group (CONT) was treated with water, the Dyslipidemic group (DL) received a high fat content emulsion throughout the experiment, and the Dyslipidemic Cashew Nuts group (DLCN) received the same high fat content emulsion throughout the experiment, yet was treated with Cashew nuts. Body parameters, biochemical, hepatic and fecal fatty acid profiles were all evaluated. The levels of total cholesterol and triglycerides were higher in the DL and DLCN groups as compared to the control group. DLCN and CONT presented no difference in HDL levels. DLCN presented higher glycemia levels than the other groups. There was reduction of body fat in DLCN as compared to other groups, but with higher accumulations of liver fat. DLCN presented a reduction in saturated hepatic fatty acids of 20.8%, and an increase of 177% in relation to CONT; there was also a 21% in increase DL for ω9 fatty acids in comparison to CONT. As for fecal fatty acids, there was a lower concentration of polysaturates in DLCN as compared to the other groups. The data showed that the consumption of Cashew nuts by the dyslipidemic animals treated with a hyperlipidic diet induced greater accumulations of liver fat and worsened glycemic levels, despite having reduced visceral fats and increased fecal fat excretion.